- Home
- CELU vs HXHX Comparison
CELU vs HXHX Comparison
Compare CELU & HXHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- HXHX
- Stock Information
- Founded
- CELU 2016
- HXHX 2003
- Country
- CELU United States
- HXHX China
- Employees
- CELU N/A
- HXHX N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- HXHX Trucking Freight/Courier Services
- Sector
- CELU Health Care
- HXHX Industrials
- Exchange
- CELU Nasdaq
- HXHX Nasdaq
- Market Cap
- CELU 37.7M
- HXHX 36.9M
- IPO Year
- CELU N/A
- HXHX 2025
- Fundamental
- Price
- CELU $2.29
- HXHX $1.36
- Analyst Decision
- CELU
- HXHX
- Analyst Count
- CELU 0
- HXHX 0
- Target Price
- CELU N/A
- HXHX N/A
- AVG Volume (30 Days)
- CELU 91.4K
- HXHX 163.7K
- Earning Date
- CELU 05-08-2025
- HXHX 01-01-0001
- Dividend Yield
- CELU N/A
- HXHX N/A
- EPS Growth
- CELU N/A
- HXHX N/A
- EPS
- CELU N/A
- HXHX 0.26
- Revenue
- CELU $54,220,000.00
- HXHX $25,571,810.00
- Revenue This Year
- CELU $23.29
- HXHX N/A
- Revenue Next Year
- CELU N/A
- HXHX N/A
- P/E Ratio
- CELU N/A
- HXHX $5.14
- Revenue Growth
- CELU 138.11
- HXHX N/A
- 52 Week Low
- CELU $1.00
- HXHX $1.29
- 52 Week High
- CELU $5.22
- HXHX $6.29
- Technical
- Relative Strength Index (RSI)
- CELU 62.18
- HXHX N/A
- Support Level
- CELU $1.90
- HXHX N/A
- Resistance Level
- CELU $2.11
- HXHX N/A
- Average True Range (ATR)
- CELU 0.28
- HXHX 0.00
- MACD
- CELU 0.07
- HXHX 0.00
- Stochastic Oscillator
- CELU 75.73
- HXHX 0.00
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.